Navigation Links
InteKrin Therapeutics' Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
Date:2/8/2010

LOS ALTOS, Calif., Feb. 8 /PRNewswire/ -- InteKrin Therapeutics Inc announced today that the Company's co-founder and Scientific Advisory Board Chairman, Christos Mantzoros, M.D., DSc., FACP, FACE, has been appointed Professor of Medicine at Harvard Medical School and Professor in Environmental Health at the Harvard School of Public Health.

Dr. Mantzoros is a member of Harvard's Division of Endocrinology, Diabetes, and Metabolism, and is an acknowledged expert in the fields of insulin resistance, body weight regulation, adipokine biology, and energy homeostasis. He has published more than 200 original papers and more than 100 reviews and chapters which have received more than 12,000 citations. He has received several national and international awards and has also been elected a member of The American Society for Clinical Investigation (ASCI).

Dr. Mantzoros, who trained at Harvard, serves as Founding Director of the Human Nutrition Research Unit and as the Clinical Research Overseer at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center. In conjunction with his new appointment, he will also be assuming responsibilities as Chief of Endocrinology and Diabetes at the Greater Boston VA Healthcare System, a system of three hospitals and six outpatient clinics in the greater Boston area which are affiliated with Harvard Medical School.

Dennis M. Lanfear, President and Chief Executive Officer, and Dr. Mantzoros founded InteKrin Therapeutics Inc in 2005. Dr. Mantzoros remains an integral part of InteKrin Therapeutics' management team and regularly advises on scientific matters.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc


'/>"/>
SOURCE InteKrin Therapeutics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
2. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
5. BioMarin to Acquire LEAD Therapeutics
6. Medical Research Council Technologys Centre for Therapeutics Discovery Opens its First Call For Targets in an Effort to Develop Drugs in Areas of Serious Unmet Need
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
9. Pepscan Therapeutics Strengthens Management Team
10. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
11. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Research and Markets has announced the ... Strategies - 2016" report to their offering. ... The latest research Autism Spectrum ... data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder and ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Menopause market? ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, 2017 ... letter to withdraw previous guidance issued by the Obama Administration requiring schools ... in May 2016 by the Obama Administration came in response to a growing ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... the La Gorce Country Club in Miami Beach to host its Swirl: Miami ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
Breaking Medicine News(10 mins):